This retrospective cohort study investigates the effectiveness of combining tumor necrosis factor inhibitor (TNFi), intravenous immunoglobulin (IVIG), & heparin in the treatment of recurrent spontaneous abortion (RSA). The study was conducted at two centers and included 60 patients with a history of RSA who received the combination therapy. The major outcome measure was the live birth rate, with pregnancy problems and adverse events as secondary outcomes. The study found that the combination therapy was connected through a major enhancement in live birth rates differentiate to previous pregnancies (70% vs. 27.5%). The pregnancy complication rate was 16.7%, and no serious adverse events were reported. The results suggest that combining TNFi, IVIG, and heparin may be a promising treatment option for patients with RSA, but more research is needed to corroborate these findings. This retrospective, two-center cohort study explores the use of a combination recurrent spontaneous abortion is treated with a necrosis factor inhibitor, intravenous immunoglobulin, and heparin. The research start that this combo therapy was implied on better pregnancy outcomes & reducing the risk of recurrent miscarriage in women who have had a history of recurrent spontaneous abortion. The study highlights the importance of individualized treatment plans for women with this condition